GlassScriptPhysician profile
Aqsa Pervez
NPI 1174273395
$1,757.75
in general payments reported to CMS, 2019-2025
24 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $263 · 2023: $554 · 2024: $369 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $412.08 | 2023-2025 | |
| Nevro Corp. | $203.49 | 2022-2024 | Senza |
| Actelion Pharmaceuticals US, INC. | $198.87 | 2023-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $159.12 | 2023-2024 | Libtayo |
| Pfizer INC. | $137.95 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Emd Serono, INC. | $117.14 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.81 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.00 | 2023-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $27.37 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $26.84 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $26.04 | 2025 | Sapien 3 Ultra Resilia |
| Ucb, INC. | $25.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.73 | 2022 | |
| Acera Surgical, INC. | $22.67 | 2025 | Restrata Wound Matrix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $22.61 | 2025 | Assure Wcd |
| Medtronic, INC. | $22.45 | 2025 | Inceptiv |
| Neurocrine Biosciences, INC. | $20.79 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.48 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $17.11 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $16.11 | 2024 | Arcalyst |
| Exact Sciences Corporation | $15.45 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $15.21 | 2025 | Arexvy, Shingrix |
| Janssen Biotech, INC. | $12.37 | 2025 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aqsa Pervez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.